Search
# Popular search #
0%
# Popular search #
Stock Code
603087.SHNew Data on Phase 1 Proposed Biosimilar Gan & Lee Insulins Aspart (GL-ASP), Lispro (GL-LIS), and Glargine (GL-GLA) Presented at the American Diabetes Association’s 81st Scientific Sessions
Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA)
Gan & Lee Pharmaceuticals to present data at the 57th Annual European Association for the Study of Diabetes Meeting
Mixed Protamine Human Insulin Injection (30R) from Gan & Lee Pharmaceuticals Approved for Listing in China
Gan & Lee receives EMA orphan drug designation for Phase I drug candidate GLR2007 for the treatment of glioma.
Gan & Lee Announces New Partnership with International Diabetes Federation
To be a world-class pharmaceutical company with focus on global business development
Our products have been approved in 18 countries
Our products have been exported to 14 countries
Our products have been studied in clinical trials in 12 countries
Our products have been approved in 18 countries
Our products have been exported to 14 countries
Our products have been studied in clinical trials in 12 countries
This website uses cookies to give users like yourself the best possible content and experience. For more information about your choices regarding cookies, please review our Privacy Policy .
The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.
